Aromatase inhibitors and breast cancer: time for a change?
Author:
- 20 December 2004
- journal article
- review article
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 58 (12) , 1152-1158
Abstract
Aromatase inhibitors bind reversibly or irreversibly to the aromatase enzyme in peripheral fat and also in the breast, leading to undetectable plasma levels of oestrogens in postmenopausal women. These agents have been shown to be more effective than tamoxifen in first‐line treatment of oestrogen receptor‐positive advanced and metastatic breast cancer. Additionally, they have been demonstrated to be superior as both adjuvant and neoadjuvant treatment. It is likely that they will also be useful for breast cancer prevention but the cost/benefit ratio has yet to be determined.Keywords
This publication has 32 references indexed in Scilit:
- An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestaneCancer, 2002
- Multicenter, Phase II Trial of Exemestane as Third-Line Hormonal Therapy of Postmenopausal Women With Metastatic Breast CancerJournal of Clinical Oncology, 1999
- Biology of aromatase inhibitors: pharmacology/endocrinology within the breast.Endocrine-Related Cancer, 1999
- Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.Journal of Clinical Oncology, 1998
- Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase ii multicentre multinational studyEuropean Journal of Cancer, 1997
- A randomized Phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinomaCancer, 1997
- A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: Endocrine and clinical resultsAnnals of Oncology, 1997
- LOW-DOSE AMINOGLUTETHIMIDE IN TREATMENT OF ADVANCED BREAST CANCERThe Lancet, 1984
- Aminoglutethimide Inhibits Extraglandular Estrogen Production in Postmenopausal Women with Breast Carcinoma*The Journal of Clinical Endocrinology & Metabolism, 1978
- Source of Estrogen Production in Postmenopausal Women1The Journal of Clinical Endocrinology & Metabolism, 1973